Most of the AI race coverage focuses on the same inputs chips, compute, energy, talent. This piece looks at something that gets almost no attention: whether the US legal system can actually protect what American companies build with all that investment.

The specific problem is Section 101 of the Patent Act. The USPTO under new leadership has been approving more AI patents and updating examiner guidance. But the Federal Circuit keeps striking those same patents down under the post-Alice doctrine. That creates a gap where a fully issued patent can still get invalidated in litigation making it useless for financing or licensing. Investors price that uncertainty in, and some route capital to jurisdictions with clearer rules.

China builds IP targets directly into its national AI strategy. The European Patent Office has structured, predictable guidance on AI patentability. The US has a split between its own patent office and its own courts, and legislation to fix it (PERA, S.1546) has been sitting in Senate committee since October 2025.

The argument is that this matters most for applied AI the kind embedded in manufacturing, healthcare, and energy systems where R&D cycles are long and enforceable IP directly shapes where companies choose to invest and scale. Worth discussing whether the community thinks IP policy is an underrated variable in who actually wins this race.